ethyl 4-(((8-hydroxyquinolin-7-yl)(phenyl)methyl)amino)benzoate | 60011-23-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ethyl 4-(((8-hydroxyquinolin-7-yl)(phenyl)methyl)amino)benzoate
• 英文别名: 4-{[(8-hydroxy-quinolin-7-yl)-phenyl-methyl]-amino}-benzoic acid ethyl ester；4-{[(8-hydroxyquinolin-7-yl)-phenyl-methyl]-amino}-benzoic acid ethyl ester；Ethyl 4-{[(8-hydroxyquinolin-7-yl)(phenyl)methyl]amino}benzoate；ethyl 4-[[(8-hydroxyquinolin-7-yl)-phenylmethyl]amino]benzoate
• CAS: 60011-23-6
• 化学式: C₂₅H₂₂N₂O₃
• 分子量: 398.461
• InChiKey: OTJPJABPMDRCJV-UHFFFAOYSA-N

物化性质

• 熔点：
  136 °C
• 沸点：
  594.4±50.0 °C(Predicted)
• 密度：
  1.270±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  71.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  苯佐卡因 、 苯甲醛 生成 ethyl 4-(((8-hydroxyquinolin-7-yl)(phenyl)methyl)amino)benzoate
  参考文献：
  名称：

  ACHARYA J. N.; THAKER K. A., J. INDIAN CHEM. SOC. , 1976, 53, NO 2, 172-173

  摘要：

  DOI：

文献信息

• [EN] 8-HYDROXY-QUINOLINE DERIVATIVES<br/>[FR] DÉRIVÉS 8-HYDROXY-QUINOLINE
  申请人：AVIDIN KUTATO FEJLESZTO ES KERESKEDELMI KORLATOLT FELELOSSEGU TARSASAG

  公开号：WO2011148208A1

  公开（公告）日：2011-12-01

  The invention relates to compounds of the general formula (I) and their pharmaceutically acceptable salts (in which formula R1 represents a hydrogen atom, lower alkyl group, lower alkenyl group, lower cycloalkyl group, aryl group, aralkyl group or heterocyclic group, wherein the above groups are optionally substituted in ortho, meta and/or para position with 1, 2, 3 or 4 electron withdrawing groups or electron donating groups; R2 represents a hydrogen atom, lower alkyl group, aryl group, aralkyl group or heterocyclic group wherein the above groups are optionally substituted with one or more halogen atoms; R3 represents a lower alkyl group, aryl group, aralkyl group or heterocyclic group wherein the above groups are optionally substituted in ortho, meta or para position with 1, 2, 3 or 4 electron withdrawing groups or electron donating groups; R4 represents a hydrogen atom, lower alkyl group or any acidic functional group; n is 1 or 2). The compounds according to the invention can be used in the medicine mainly for the treatment of diseases associated with neurological and/or oxidative stress.

  该发明涉及通式(I)的化合物及其药用可接受的盐（其中通式中R1代表氢原子、较低的烷基、较低的烯基、较低的环烷基、芳基、芳基烷基或杂环基，上述基团可以选择性地在邻位、间位和/或对位上用1、2、3或4个电子吸引基团或电子供给基团替代；R2代表氢原子、较低的烷基、芳基、芳基烷基或杂环基，上述基团可以选择性地用一个或多个卤素原子替代；R3代表较低的烷基、芳基、芳基烷基或杂环基，上述基团可以选择性地在邻位、间位或对位上用1、2、3或4个电子吸引基团或电子供给基团替代；R4代表氢原子、较低的烷基或任何酸性官能团；n为1或2）。根据该发明的化合物主要可用于治疗与神经和/或氧化应激有关的疾病。
• 8-HYDROXY-QUINOLINE DERIVATIVES
  申请人：Puskas Laszlo

  公开号：US20130131096A1

  公开（公告）日：2013-05-23

  The invention relates to compounds of the general formula (I) and their pharmaceutically acceptable salts (in which formula R 1 represents a hydrogen atom, lower alkyl group, lower alkenyl group, lower cycloalkyl group, aryl group, aralkyl group or heterocyclic group, wherein, the above groups are optionally substituted in ortho, meta and/or para position with 1, 2, 3 or 4 electron withdrawing groups or electron donating groups; R 2 represents a hydrogen atom, lower alkyl group, aryl group, aralkyl group or heterocyclic group wherein the above groups are optionally substituted with one or more halogen atoms; R 3 represents a lower alkyl group, aryl group, aralkyl group or heterocyclic group wherein the above groups are optionally substituted in ortho, meta or para position with 1, 2, 3 or 4 electron withdrawing groups or electron donating groups; R 4 represents a hydrogen atom, lower alkyl group or any acidic functional group; n is 1 or 2). The compounds according to the invention can be used in the medicine mainly for the treatment of diseases associated with neurological and/or oxidative stress.

  本发明涉及一般式（I）的化合物及其药学上可接受的盐（其中R1表示氢原子，低碳基，低烯基，低环烷基，芳基，芳基烷基或杂环基，其中上述基团在邻位，间位和/或对位上可以选择性地被1、2、3或4个电子提取基团或电子捐赠基团取代；R2表示氢原子，低碳基，芳基，芳基烷基或杂环基，其中上述基团可以选择性地被一个或多个卤素原子取代；R3表示低碳基，芳基，芳基烷基或杂环基，其中上述基团在邻位，间位或对位上可以选择性地被1、2、3或4个电子提取基团或电子捐赠基团取代；R4表示氢原子，低碳基或任何酸性官能团；n为1或2）。根据本发明的化合物主要可用于治疗与神经学和/或氧化应激相关的疾病。
• 8-Hydroxyquinoline-based inhibitors of the Rce1 protease disrupt Ras membrane localization in human cells
  作者：Idrees Mohammed、Shahienaz E. Hampton、Louise Ashall、Emily R. Hildebrandt、Robert A. Kutlik、Surya P. Manandhar、Brandon J. Floyd、Haley E. Smith、Jonathan K. Dozier、Mark D. Distefano、Walter K. Schmidt、Timothy M. Dore

  DOI：10.1016/j.bmc.2015.11.043

  日期：2016.1

  Ras converting enzyme 1 (Rce1) is an endoprotease that catalyzes processing of the C-terminus of Ras protein by removing -aaX from the CaaX motif. The activity of Rce1 is crucial for proper localization of Ras to the plasma membrane where it functions. Ras is responsible for transmitting signals related to cell proliferation, cell cycle progression, and apoptosis. The disregulation of these pathways due to constitutively active oncogenic Ras can ultimately lead to cancer. Ras, its effectors and regulators, and the enzymes that are involved in its maturation process are all targets for anti-cancer therapeutics. Key enzymes required for Ras maturation and localization are the farnesyltransferase (FTase), Rce1, and isoprenylcysteine carboxyl methyltransferase (ICMT). Among these proteins, the physiological role of Rce1 in regulating Ras and other CaaX proteins has not been fully explored. Small-molecule inhibitors of Rce1 could be useful as chemical biology tools to understand further the downstream impact of Rce1 on Ras function and serve as potential leads for cancer therapeutics. Structure-activity relationship (SAR) analysis of a previously reported Rce1 inhibitor, NSC1011, has been performed to generate a new library of Rce1 inhibitors. The new inhibitors caused a reduction in Rce1 in vitro activity, exhibited low cell toxicity, and induced mislocalization of EGFP-Ras from the plasma membrane in human colon carcinoma cells giving rise to a phenotype similar to that observed with siRNA knockdowns of Rce1 expression. Several of the new inhibitors were more effective at mislocalizing K-Ras compared to a potent farnesyltransferase inhibitor (FTI), which is significant because of the preponderance of K-Ras mutations in cancer. (C) 2015 Elsevier Ltd. All rights reserved.
• US8871937B2
  申请人：——

  公开号：US8871937B2

  公开（公告）日：2014-10-28
• ACHARYA J. N.; THAKER K. A., J. INDIAN CHEM. SOC. <JICS-AH>, 1976, 53, NO 2, 172-173
  作者：ACHARYA J. N.、 THAKER K. A.

  DOI：——

  日期：——